Intravitreal bevacizumab (Avastin®) for neovascular age-related macular degeneration in treatment-naive patients

Acta Ophthalmologica

Volumn 87, Issue 7, 2009, Pages 714-719

  Pedersen, Karen Bjerg ^a   Sjølie, Anne Katrin ^a   Møller, Flemming ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Age related macular degeneration; Intravitreal bevacizumab; Neovascularization; Optical coherence tomography; Pigment epithelial detachment

Indexed keywords

BEVACIZUMAB; CHLORAMPHENICOL; OXYBUPROCAINE; POVIDONE IODINE; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARGON LASER; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST SENSITIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INFECTION; INJURY; MALE; OPHTHALMOLOGY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; INJECTION; MACULAR DEGENERATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; CONTRAST SENSITIVITY; FEMALE; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 72349086232     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01346.x     Document Type: Article

References (24)

1. Adamis AP Shima DT (2005 The role of vascular endothelial growth factor in ocular health and disease. Retina 25 : 111 118.
2. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA Giust MJ (2006 Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 : 363 372.
3. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP Noureddin BN (2006 Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 : 1 9.
4. Bird AC, Bressler NM, Bressler SB et al. (1995 An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39 : 367 374.
5. Bom AF, Eid FM Melo GB (2006 Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Acta Ophthalmol Scand 84 : 713 714.
6. Buch H, Nielsen NV, Vinding T, Jensen GB, Prause JU la CM (2005 14-year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study. Ophthalmology 112 : 787 798. (Pubitemid 40631497)
7. Cohen MH, Gootenberg J, Keegan P Pazdur R (2007 FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12 : 713 718.
8. Emerson MV, Lauer AK, Flaxel CJ et al. (2007 Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27 : 439 444.
9. Falkenstein IA, Cheng L, Morrison VL, Kozak I, Tammewar AM Freeman WR (2007 Standardized visual acuity results associated with primary versus secondary bevacizumab (avastin) treatment for choroidal neovascularization in age-related macular degeneration. Retina 27 : 701 706.
10. Ferrara N, Gerber HP LeCouter J (2003 The biology of VEGF and its receptors. Nat Med 9 : 669 676.
11. Ferrara N, Hillan KJ Novotny W (2005 Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333 : 328 335.
12. Ferris FL III., Kassoff A, Bresnick GH Bailey I (1982 New visual acuity charts for clinical research. Am J Ophthalmol 94 : 91 96.
13. Ferris FL III., Fine SL Hyman L (1984 Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102 : 1640 1642.
14. Jonas JB, Libondi T, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F, Sauder G Spandau UH (2007 Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 85 : 563 565.
15. Kaiser PK, Blodi BA, Shapiro H Acharya NR (2007 Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114 : 1868 1875.
16. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M Gangnon RE (2007 Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 114 : 253 262.
17. Lazic R Gabric N (2007 Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245 : 68 73.
18. Pedersen R, Soliman W, Lund-Andersen H Larsen M (2007 Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 85 : 526 533.
19. Rich RM, Rosenfeld PJ, Puliafito CA et al. (2006 Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 : 495 511.
20. Rosenfeld PJ, Moshfeghi AA Puliafito CA (2005 Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 : 331 335.
21. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY Kim RY (2006 Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 : 1419 1431.
22. Soliman W, Lund-Andersen H Larsen M (2006 Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization. Acta Ophthalmol Scand 84 : 707 708.
23. Spaide RF, Laud K, Fine HF et al. (2006 Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 : 383 390. (Pubitemid 44197628)
24. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK Fastenberg DM (2006 Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26 : 994 998.